Cardiovascular Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cardiovascular Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
AVI BioPharma, Inc.
Final results reported from Resten-NG AVAIL trial
December 7th, 2004
AVI BioPharma, Inc., (AVII) announced positive results from its AVAIL phase II clinical trial, which investigated the effects of antisense drug Resten-NG against cardiovascular restenosis. Resten-NG is a third-generation Neugene antisense drug targeting the key regulatory gene in restenosis. It is the most advanced antisense agent in development by AVI. Nicholas Kipshidze, MD, an interventional cardiologist from Lenox Hill Hospital in New York, presented the results at the American Heart Association's annual meeting in New Orleans. The AVAIL multicenter clinical study enrolled coronary artery disease patients who had a high risk of restenosis...
Source: Cardiovascular Business Week (2004-12-07)
|
